Transplantation in Parkinson's disease using human embryonic stem cell (hESC)-derived
dopaminergic (DA) neurons is a promising future treatment option. However, many of the …

Background: Cell transplantation is expected to be a promising treatment for Parkinson's
disease (PD), in which re-innervation of the host striatum by grafted dopamine (DA) neurons …

Neurodegenerative disease is a brain disorder caused by the loss of structure and function
of neurons that lowers the quality of human life. Apart from the limited potential for …

Neurons derived from human pluripotent stem cells (hPSCs) provide a valuable tool for
studying human neural development and neurodegenerative diseases. The investigation of …

Mesencephalic dopaminergic (mDA) neurons derived from pluripotent stem cells (PSCs)
have proven to be pivotal for disease modeling studies and as a source of transplantable …

Recent advances in cell reprogramming have made it possible to form new therapeutic cells
within the body itself via a process called direct conversion or lineage reprogramming. A …

Cell replacement therapies hold the potential to restore neuronal networks compromised by
neurodegenerative diseases (such as Parkinson's disease or Huntington's disease), or focal …

A major limiting factor for cell therapy in Parkinson's disease is the poor survival and
reinnervation capacity of grafted dopaminergic neurons, independently of the cell source …

Parkinson's disease (PD) is the second most common neurodegenerative disease and a
prime target of cell therapies. In fact, aborted fetal tissue has been used as donor material for …

Fetal neural progenitor grafts have been evaluated in preclinical animal models of spinal
cord injury and Parkinson's disease for decades, but the initial reliance on primary tissue as …